Skip to main content

Table 1 Patient Characteristics and Response Rates

From: Talimogene Laherparepvec combined with anti-PD-1 based immunotherapy for unresectable stage III-IV melanoma: a case series

Consecutive Patients (n = 10)
Sex Male = 7, Female = 3
Median Age (range) 70 (52–82)
Follow-up Time 4.5–13.6 Months
ECOG Performance Score 0 = 5, 1 = 4, 2 = 1
Patients with Distant Metastases 2
Unresectale Stage III 8
Stage IV 2
Prior exposure to immunotherapy (1 adjuvant therapy, 2 systemic therapies)
Prior exposure to targeted therapy 1
Overall Response Rate (On-target lesions) 9/10
Overall Response Rate(Off-target lesions) 2/2